1Mesa RA, Elliott MA, Schroeder G. Durable responses to thalidomide- based drug therapy for myelofibrosis with myeloid metaplasia [J]. Mayo Clin Proe,2004 ;79 (7) : 883-9.
2Piccaluga PP, Visani G, Pileri SA, et al. Clinical efficacy and antiangio- genie activity of thalidomide in myelofibrosis with myeloid metaplasia. A pilot study[J]. Leukemia,2002 ; 16 ( 9 ) : 1609-14.
3Thomas DA, Giles FJ, Albitar M, et al. Thalidomide therapy for myelofi- brosis with myeloid metaplasia( J]. Cancer,2006 ; 106 ( 9 ) : 1974-84.
2SPIVAK J L,BAROSI G,TOGNON I G,et al.Chronic Myeloproliferative Disorders[J].Hematology,2003.200-224.
3MESA R A,HANSON C A,RAJKUMAR S V,et al.Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia[J].Blood,2000,96:3374-3380.
4MESA R A,STEENSMA D P,PARDANANI A,et al.A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia[J].Blood,2003,101:2534-41.
5PICCALUGA P P,VISANI G,PILERI S A,et al.Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia.A pilot study[J].Leukemia,2002,16:1609-1614.
